Ana Farinha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ana Farinha has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- António Inácio
Nephrology, Unidade Local de Saúde da Arrábida, Setúbal, Portugal
5 shared publications - Ana Piedade
Universidade Politécnica de Beja
4 shared publications - Patrícia Domingues
Division of Nephrology and Hypertension , Mayo Clinic, Rochester, MN
4 shared publications - Beatriz Vaz de Melo Mendes
Federal University at Rio de Janeiro
3 shared publications - Karina Soto
Unidade Local de Saúde da Arrábida
3 shared publications Patricia Valério Santos
Setubal Hospital Center, Nephrology, Portugal
3 shared publications
Latest Publications
- 26 August 2026
- Published by SAGE Publications in Journal of Onco-Nephrology
Kidney-limited IgG3κ-PGNMID: A case report and narrative review
Proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID) is a rare form of monoclonal gammopathy of renal significance, most commonly associated with IgG3-restricted deposits. In many patients, however, a circulating monoclonal protein or clonal plasma cell disorder cannot be identified, complicating therapeutic decision-making. We report the case of a 70-year-old woman presenting with nephrotic syndrome and progressive kidney dysfunction. Kidney biopsy demonstrated a membranoproliferative pattern with IgG3κ-restricted glomerular deposits, establishing the diagnosis of IgG3κ-PGNMID. Extensive hematologic evaluation including serum and urine immunofixation, serum free light chains, bone marrow biopsy with flow cytometry and cytogenetics, fluorescence in situ hybridization, and PET–CT revealed no detectable clonal plasma cell disorder. Despite optimized supportive therapy, kidney function deteriorated rapidly, with serum creatinine rising to 4.45 mg/dL and proteinuria exceeding 10 g/g. Empirical clone-directed therapy with daratumumab, bortezomib, melphalan, and prednisone (Dara-VMP) was initiated. An improvement in kidney function was observed, with proteinuria decreasing to 0.7 g/day after nine treatment cycles and stabilization of serum creatinine at approximately 2.0 mg/dL. Maintenance daratumumab therapy was subsequently continued. At 17 months of follow-up, the patient remains in partial renal remission with stable kidney function. This case supports the potential role of daratumumab-based therapy in patients with progressive PGNMID even when extensive hematologic evaluation fails to identify a clonal disorder.
- 26 August 2026
- Published by SAGE Publications in Journal of Onco-Nephrology
Kidney-limited IgG3κ-PGNMID: A case report and narrative review
Proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID) is a rare form of monoclonal gammopathy of renal significance, most commonly associated with IgG3-restricted deposits. In many patients, however, a circulating monoclonal protein or clonal plasma cell disorder cannot be identified, complicating therapeutic decision-making. We report the case of a 70-year-old woman presenting with nephrotic syndrome and progressive kidney dysfunction. Kidney biopsy demonstrated a membranoproliferative pattern with IgG3κ-restricted glomerular deposits, establishing the diagnosis of IgG3κ-PGNMID. Extensive hematologic evaluation including serum and urine immunofixation, serum free light chains, bone marrow biopsy with flow cytometry and cytogenetics, fluorescence in situ hybridization, and PET–CT revealed no detectable clonal plasma cell disorder. Despite optimized supportive therapy, kidney function deteriorated rapidly, with serum creatinine rising to 4.45 mg/dL and proteinuria exceeding 10 g/g. Empirical clone-directed therapy with daratumumab, bortezomib, melphalan, and prednisone (Dara-VMP) was initiated. An improvement in kidney function was observed, with proteinuria decreasing to 0.7 g/day after nine treatment cycles and stabilization of serum creatinine at approximately 2.0 mg/dL. Maintenance daratumumab therapy was subsequently continued. At 17 months of follow-up, the patient remains in partial renal remission with stable kidney function. This case supports the potential role of daratumumab-based therapy in patients with progressive PGNMID even when extensive hematologic evaluation fails to identify a clonal disorder.
- Open Access
- 21 October 2025
- Published by Springer Nature in Research Square
Assessment of European health professionals' educational needs in basic principles of Geriatric Medicine: a focus group qualitative analysis from the PROGRAMMING COST Action 21122
Purpose Europe’s ageing population necessitates high quality care for older people. However, in many countries geriatrics is still emerging as a specialty, with limited training options for healthcare professionals (HCPs). This international qualitative study aimed to understand the geriatric educational needs of HCPs, focusing on countries where Geriatric Medicine (GM) is emerging or underdeveloped. Methods Fourteen focus groups (n = 125 participants) were carried out representing 11 European countries and a range of HCPs and settings. Focus groups were recorded, transcribed verbatim and inductively coded in the original language. Codes were aggregated into a shared English codebook which was applied to all transcripts. Descriptive and subsequently analytical themes were then developed. Results Three themes were identified: 1) Current experiences of geriatric care: Participants described caring for older adults as medically and socially complex, requiring strong communication skills and interprofessional collaboration. 2) Structural and contextual challenges: Limited staffing, fragmented care pathways, and the emerging status of GM hindered effective care delivery, and 3) Uncertainties and unmet training needs: Key uncertainties included distinguishing ageing from disease, applying assessment tools, recognising red flags, and safe medication management. Participants emphasised the need for practical training during undergraduate studies, standardised interprofessional courses for non-specialists, and structural support (e.g., accessible programs and protected time for training). Conclusion Our focus group study outlines the limitations of current training and provides a framework for developing relevant and feasible training for HCPs working with older people. Structural support is needed for these initiatives to improve European geriatric care.
- 21 October 2025
- Published by Springer Nature in Research Square
Open AccessAssessment of European health professionals' educational needs in basic principles of Geriatric Medicine: a focus group qualitative analysis from the PROGRAMMING COST Action 21122
Purpose Europe’s ageing population necessitates high quality care for older people. However, in many countries geriatrics is still emerging as a specialty, with limited training options for healthcare professionals (HCPs). This international qualitative study aimed to understand the geriatric educational needs of HCPs, focusing on countries where Geriatric Medicine (GM) is emerging or underdeveloped. Methods Fourteen focus groups (n = 125 participants) were carried out representing 11 European countries and a range of HCPs and settings. Focus groups were recorded, transcribed verbatim and inductively coded in the original language. Codes were aggregated into a shared English codebook which was applied to all transcripts. Descriptive and subsequently analytical themes were then developed. Results Three themes were identified: 1) Current experiences of geriatric care: Participants described caring for older adults as medically and socially complex, requiring strong communication skills and interprofessional collaboration. 2) Structural and contextual challenges: Limited staffing, fragmented care pathways, and the emerging status of GM hindered effective care delivery, and 3) Uncertainties and unmet training needs: Key uncertainties included distinguishing ageing from disease, applying assessment tools, recognising red flags, and safe medication management. Participants emphasised the need for practical training during undergraduate studies, standardised interprofessional courses for non-specialists, and structural support (e.g., accessible programs and protected time for training). Conclusion Our focus group study outlines the limitations of current training and provides a framework for developing relevant and feasible training for HCPs working with older people. Structural support is needed for these initiatives to improve European geriatric care.
- Open Access
- 14 June 2023
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 38 (Supplement)
#4781 FRAILTY IN PERITONEAL DIALYSIS: PREVALENCE AND PREDICTION FACTORS
Frailty is a clinical syndrome characterized by a state of increased vulnerability and risk of adverse outcomes following a stress, which exerts a heavy economic and social burden. The identification of this syndrome is done throught validated tools. Although frailty is associated with advanced age, certain conditions that produce age-like changes can lead to a state of frailty at younger ages. The presence of multiple comorbidities increases frailty risk. Also, low levels of albumin, even in the normal range, have been related to greater frailty and its levels have been used to assess frailty. Chronic kidney disease is associated with higher prevalence of frailty. However, little has been reported about frailty prevalence in peritoneal dialysis population. Our aim was to access the prevalence of frail and vulnerable PD patients using the Edmonton Frailty Scale (EFS) and to identify prediction factors. In a retrospective cohort study, we assessed frailty in PD patients from 2 center in Portugal by a validated frailty score (Edmonton Frailty Scale-EFS). We also collected information that could contribute to frailty in these patients. Linear and logistic regressions were used to access frailty predictors. Receiver operating characteristics (ROC) curve was used to access accuracy of those predictors. We included 74 PD patients, 51,5% male, mean age 53,9 ± 15,1 years, median body max index 25,2 ± 4,3 Kg/m2. Median CCI was 4 [interquartile range (IQR) of 3]. Fifty-three patients (71,6%) were classified as robust (non-frail), 11 as vulnerable, and 10 as frail (8 mildly and 2 moderate). Patients were divided into two groups: A group included robust (non-frail) patients; B group included vulnerable and frail ones. Age, sex distribution, IMC, diabetes mellitus prevalence, variables related to PD (efficacy, vintage, modality and complications), and levels of hemoglobin, phosphorus, potassium and C-reactive protein were similar between the groups. Non frail patients presented significantly higher albumin levels and lower CCI (p-value < 0,05). A linear regression was performed to ascertain the effects of CCI and albumin: CCI was an independent predictor for frailty/vulnerability, accessed by EFS (for each point in CCI, there was an increase of 0,5 points in EFS). Albumin did not show a significant effect defining frailty in our sample. ROC curve showed a high accuracy for CCI to identify frail/ vulnerable patients (AUC 0,817). In our sample, CCI was an independent factor for frailty/vulnerability classified through EFS. In fact, it had a high accuracy to identify those patients, with a high sensibility. This means that CCI could be used as an acceptable screening test. However, the prevalence of frail/vulnerable patients was low in our sample. A larger one will allow to determine confirm if certain comorbidities, such as diabetes mellitus, or variables related to dialysis technique, are correlated with frailty. Furthermore, a larger sample would be essential to confirm whether albumin is, after all, a good predictor of frailty in the PD population, which was not confirmed in this work.
- 14 June 2023
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 38 (Supplement)
Open Access#4781 FRAILTY IN PERITONEAL DIALYSIS: PREVALENCE AND PREDICTION FACTORS
Frailty is a clinical syndrome characterized by a state of increased vulnerability and risk of adverse outcomes following a stress, which exerts a heavy economic and social burden. The identification of this syndrome is done throught validated tools. Although frailty is associated with advanced age, certain conditions that produce age-like changes can lead to a state of frailty at younger ages. The presence of multiple comorbidities increases frailty risk. Also, low levels of albumin, even in the normal range, have been related to greater frailty and its levels have been used to assess frailty. Chronic kidney disease is associated with higher prevalence of frailty. However, little has been reported about frailty prevalence in peritoneal dialysis population. Our aim was to access the prevalence of frail and vulnerable PD patients using the Edmonton Frailty Scale (EFS) and to identify prediction factors. In a retrospective cohort study, we assessed frailty in PD patients from 2 center in Portugal by a validated frailty score (Edmonton Frailty Scale-EFS). We also collected information that could contribute to frailty in these patients. Linear and logistic regressions were used to access frailty predictors. Receiver operating characteristics (ROC) curve was used to access accuracy of those predictors. We included 74 PD patients, 51,5% male, mean age 53,9 ± 15,1 years, median body max index 25,2 ± 4,3 Kg/m2. Median CCI was 4 [interquartile range (IQR) of 3]. Fifty-three patients (71,6%) were classified as robust (non-frail), 11 as vulnerable, and 10 as frail (8 mildly and 2 moderate). Patients were divided into two groups: A group included robust (non-frail) patients; B group included vulnerable and frail ones. Age, sex distribution, IMC, diabetes mellitus prevalence, variables related to PD (efficacy, vintage, modality and complications), and levels of hemoglobin, phosphorus, potassium and C-reactive protein were similar between the groups. Non frail patients presented significantly higher albumin levels and lower CCI (p-value < 0,05). A linear regression was performed to ascertain the effects of CCI and albumin: CCI was an independent predictor for frailty/vulnerability, accessed by EFS (for each point in CCI, there was an increase of 0,5 points in EFS). Albumin did not show a significant effect defining frailty in our sample. ROC curve showed a high accuracy for CCI to identify frail/ vulnerable patients (AUC 0,817). In our sample, CCI was an independent factor for frailty/vulnerability classified through EFS. In fact, it had a high accuracy to identify those patients, with a high sensibility. This means that CCI could be used as an acceptable screening test. However, the prevalence of frail/vulnerable patients was low in our sample. A larger one will allow to determine confirm if certain comorbidities, such as diabetes mellitus, or variables related to dialysis technique, are correlated with frailty. Furthermore, a larger sample would be essential to confirm whether albumin is, after all, a good predictor of frailty in the PD population, which was not confirmed in this work.
- Open Access
- 14 June 2023
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 38 (Supplement)
#4790 SERUM BIOMARKERS AS PREDICTORS OF RENAL DAMAGE IN ANCA-ASSOCIATED VASCULITIDES
Despite therapeutic advances, anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) carry poor renal and survival outcomes. Prognostic elements are needed to guide treatment. Several studies explored determinants of AAV outcomes, but predictive factors are not well established. Poor prognosis factors have been lower glomerular filtration rate, lower serum C3, C3 deposition on immunofluorescence (IF), and recently platelet count below 250 × 109/L. Histopathological lesions have also been related to renal outcomes. In this study we aim to correlate serum immune and inflammatory biomarkers with renal histological lesions’ severity. We retrospectively analysed histopathological findings of adults with biopsy-proven AAV renal involvement through Berden's histopathological classification (BHC) classes, Brix's renal risk score (BRS), interstitial fibrosis and tubular atrophy (IFTA) and crescentic glomeruli percentages (%), C3 positive IF and presence of interstitial hemorrhage (IH). Patients’ ANCA titer (ANCAd) measured by ELISA, serum C3 and C-reactive protein (CRP) were documented at diagnosis. ANCA titer was also registered at last follow-up date (ANCAf). Univariate statistical analysis was used to correlate every biomarker with every histologic variable mentioned. C3 and CRP were used as continuous variables and ANCA titers as continuous and categorical variables. As a continuous variable, ANCA titers above laboratorial detection were not considered (i.e. >134). Seronegative AAV were not considered for titer analysis. BRS was considered as continuous variable for its score and as categorical for its risk group. Multivariate analysis was used to identify independent predictors renal biopsy findings. We included 46 patients with biopsy-proven AAV kidney involvement from January 2006 to January 2023, 65.2% male (n = 30), median age 66.5 (60.75-74.5), 78.3% (36) MPO, 15.2% (7) PR3 and 6.5% (3) seronegative; and 6.5% (3) had concomitant anti-GBM+ (all MPO). Categorization by ANCAd revealed 7.7% (3) 0-19 UI/mL, 7.7% (3) 20-39, 7.7% (3) 40-59, 20.5% (8) 60-99, 12.8% (5) 100-134 and 43.6% >134. According to BHC, biopsies were: 17.4% (8) global sclerotic, 28.3% (13) mixed, 39.1% (18) crescentic, and 15.2% (7) focal. According to BRS, 2.2% (1) had low risk, 28.3% (13) medium risk and 58.7% (27) high risk of ESKD. 5 biopsies had incomplete information for a score result. Median BRS was 9 – high risk. IF C3 was positive 28.3% (16) biopsies, and IH in 10.9% (5). Median % IFTA was 40% and median %crescentic was 33%. In univariate analysis, ANCAd did not correlate to BHC class both as continuous and categorical variable (p = 0.477 and p = 0.685 respectively), nor to %IFTA (p = 0.935, p = 0.938), nor %crescents (p = 0.975, p = 0.938), nor C3 IF staining (p = 0.690, p = 0.344), nor IH presence (p = 0.773, p = 0.897), nor to BRS risk groups (p = 0.339, p = 0.584). ANCAd titer did not correlate to BRS score value (p = 0.072, r = 0.372), both as continous variables. However, ANCAf did correlate to BRS´s risk groups (p = 0.037), with ANCAf values higher in the high-risk compared to the medium-risk group (p = 0.016). In multivariate analysis including age and gender, ANCAf persists as a predictor of BRS´s risk groups (p<0.001, model p<0.001). C3 levels at diagnosis did not have statistically significant correlation with neither histological finding: BHC class (p = 0.282), BRS score (p = 0.683), % IFTA (p = 0.753), % crescents (p = 0.989), C3 on IF (p = 0.472) and IH (p = 0.773). No significant correlation was seen when considering CRP at diagnosis: BHC class (p = 0.162), BRS (p = 0.276), %IFTA (p = 0.343), %crescents (p = 0.071), C3 on IF (p = 0.657) and IH (p = 0.951). ANCA titer at diagnosis, serum C3 and CRP did not correlate with histological severity and chronicity lesions in our population. Nonetheless, larger cohorts, systematization of biopsy findings and studies on newer biomarkers might bring helpful information to expected prognosis and initial therapeutic approaches. A positive correlation between ANCA levels at the last follow-up date and medium and high-risk BRS groups on initial biopsy might be further explored in larger studies.
- 14 June 2023
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 38 (Supplement)
Open Access#4790 SERUM BIOMARKERS AS PREDICTORS OF RENAL DAMAGE IN ANCA-ASSOCIATED VASCULITIDES
Despite therapeutic advances, anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) carry poor renal and survival outcomes. Prognostic elements are needed to guide treatment. Several studies explored determinants of AAV outcomes, but predictive factors are not well established. Poor prognosis factors have been lower glomerular filtration rate, lower serum C3, C3 deposition on immunofluorescence (IF), and recently platelet count below 250 × 109/L. Histopathological lesions have also been related to renal outcomes. In this study we aim to correlate serum immune and inflammatory biomarkers with renal histological lesions’ severity. We retrospectively analysed histopathological findings of adults with biopsy-proven AAV renal involvement through Berden's histopathological classification (BHC) classes, Brix's renal risk score (BRS), interstitial fibrosis and tubular atrophy (IFTA) and crescentic glomeruli percentages (%), C3 positive IF and presence of interstitial hemorrhage (IH). Patients’ ANCA titer (ANCAd) measured by ELISA, serum C3 and C-reactive protein (CRP) were documented at diagnosis. ANCA titer was also registered at last follow-up date (ANCAf). Univariate statistical analysis was used to correlate every biomarker with every histologic variable mentioned. C3 and CRP were used as continuous variables and ANCA titers as continuous and categorical variables. As a continuous variable, ANCA titers above laboratorial detection were not considered (i.e. >134). Seronegative AAV were not considered for titer analysis. BRS was considered as continuous variable for its score and as categorical for its risk group. Multivariate analysis was used to identify independent predictors renal biopsy findings. We included 46 patients with biopsy-proven AAV kidney involvement from January 2006 to January 2023, 65.2% male (n = 30), median age 66.5 (60.75-74.5), 78.3% (36) MPO, 15.2% (7) PR3 and 6.5% (3) seronegative; and 6.5% (3) had concomitant anti-GBM+ (all MPO). Categorization by ANCAd revealed 7.7% (3) 0-19 UI/mL, 7.7% (3) 20-39, 7.7% (3) 40-59, 20.5% (8) 60-99, 12.8% (5) 100-134 and 43.6% >134. According to BHC, biopsies were: 17.4% (8) global sclerotic, 28.3% (13) mixed, 39.1% (18) crescentic, and 15.2% (7) focal. According to BRS, 2.2% (1) had low risk, 28.3% (13) medium risk and 58.7% (27) high risk of ESKD. 5 biopsies had incomplete information for a score result. Median BRS was 9 – high risk. IF C3 was positive 28.3% (16) biopsies, and IH in 10.9% (5). Median % IFTA was 40% and median %crescentic was 33%. In univariate analysis, ANCAd did not correlate to BHC class both as continuous and categorical variable (p = 0.477 and p = 0.685 respectively), nor to %IFTA (p = 0.935, p = 0.938), nor %crescents (p = 0.975, p = 0.938), nor C3 IF staining (p = 0.690, p = 0.344), nor IH presence (p = 0.773, p = 0.897), nor to BRS risk groups (p = 0.339, p = 0.584). ANCAd titer did not correlate to BRS score value (p = 0.072, r = 0.372), both as continous variables. However, ANCAf did correlate to BRS´s risk groups (p = 0.037), with ANCAf values higher in the high-risk compared to the medium-risk group (p = 0.016). In multivariate analysis including age and gender, ANCAf persists as a predictor of BRS´s risk groups (p<0.001, model p<0.001). C3 levels at diagnosis did not have statistically significant correlation with neither histological finding: BHC class (p = 0.282), BRS score (p = 0.683), % IFTA (p = 0.753), % crescents (p = 0.989), C3 on IF (p = 0.472) and IH (p = 0.773). No significant correlation was seen when considering CRP at diagnosis: BHC class (p = 0.162), BRS (p = 0.276), %IFTA (p = 0.343), %crescents (p = 0.071), C3 on IF (p = 0.657) and IH (p = 0.951). ANCA titer at diagnosis, serum C3 and CRP did not correlate with histological severity and chronicity lesions in our population. Nonetheless, larger cohorts, systematization of biopsy findings and studies on newer biomarkers might bring helpful information to expected prognosis and initial therapeutic approaches. A positive correlation between ANCA levels at the last follow-up date and medium and high-risk BRS groups on initial biopsy might be further explored in larger studies.
- Open Access
- 14 June 2023
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 38 (Supplement)
#6035 PREDICTORS OF MORTALITY IN ANCA-ASSOCIATED VASCULITIS: WHAT IS THE ROLE OF SERUM BIOMARKERS?
Background and Aims: ANCA-Associated vasculitis (AAV) is an autoimmune disease with necrotizing inflammation of small vessels as the main manifestation. AAV is a severe disease with high level of mortality. Severity markers are needed to better tailor treatment. ANCA titers have not always been correlated with disease severity and mortality. Other inflammation markers have also been used such as C3 and C-reactive protein (CRP). The aim of this study is to correlate ANCA titers, C3 and CPR values with mortality in patients with renal vasculitis. Method: We retrospectively analyzed all adult patients between June 2006 and December 2022 with a renal AAV in the nephrology department of São Bernardo Hospital. Demographic, clinical and laboratory findings of all patients were recorded. ANCA titers at the time of diagnosis (ANCAd), remission (ANCArm), relapse (ANCArl) and last follow-up (ANCAf) dates were registered. C3 levels were measured at diagnosis (dC3) and at the last follow-up (fC3) dates. CRP was measured at diagnosis (CRPd), remission (CRPrm) and last follow-up (CRPf). ANCA titers was analysed as continuous and categorical variables. C3 and CRP were used as continuous variables. We analyse the association between ANCA titers, C3, CPR values and mortality with univariate analysis. Multivariable adjusted cox regression analysis was performed for assessing predictive variables associated with mortality. Results: We included 58 AAV patients with kidney involvement, with mean age of 69±10 years old, 54.4% were male (n = 31), 82.7% (n = 48) MPO-ANCA+, 12.1% (n = 7) PR3-ANCA+ and 5.2% (n = 3) seronegative. Median follow-up was 32.2 months. 20 (34.5%) patients died. At admission, categorization by ANCA titer revealed 5.2% (3) 0-19 UI/mL, 10.3% (6) 20-39, 8.6% (5) 40-59, 17.2% (10) 60-99, 8.6% (5) 100-134 and 38% >134 (22). C3 median was 109 UI/L at admission, 96.5 UI/L at last follow-up, CPR median was 7.9 mg/dL at admission, 2.4 mg/dL at last follow-up. Univariate analysis did not reveal a difference between patients who survived and those who died, in relation to ANCAd (p = 0.221), ANCArm (p = 0.346), ANCArl (p = 0.180) and ANCAf (p = 0.072). However, it did show that dC3 where significantly lower in those patients who died (p = 0.023) and CRPf higher (p = 0.012), but not for fC3 (p = 0.372), CRPd (p = 0.408) and CRPrm (p = 0.384). Used as categorical variable, ANCAd did not correlate to patients’ death occurrence (p = 0.788). In multivariate analysis including age, gender, dC3 and CRPf, only CRPf was almost significantly (p = 0,06, model p = 0,05). In univariate cox regression analysis to evaluate factors related to survival, none where statistic significant to predict dead – ANCA d (p = 0,349), ANCAf (p = 0.136), dC3 (p = 0.082) and CRPf (p = 0.066). In multivariate cox regression analysis, including age (p = 0.039), gender (p = 0.658), dC3 (p = 0.227) and CRPf (p = 0.639), none factor predict dead (model p = 0,08). Conclusion: In our cohort of patients with AAV, we did not found a serologic marker to predict dead. However, it appears to have a relationship with low serum C3 levels at the time of diagnosis. We also found that could be a relationship with CRP at the last follow-up, but that could be a bias due to higher levels in those how died from infection causes. The diagnostic value of the PR3- and MPO ANCA test is well established, however the relationship between mortality and titer levels in the various stages of the disease is not well established. In our study, there was no association between them. Further research should determine whether C3 levels and CPR are indeed an independent predictor of AAV outcome.
- 14 June 2023
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 38 (Supplement)
Open Access#6035 PREDICTORS OF MORTALITY IN ANCA-ASSOCIATED VASCULITIS: WHAT IS THE ROLE OF SERUM BIOMARKERS?
Background and Aims: ANCA-Associated vasculitis (AAV) is an autoimmune disease with necrotizing inflammation of small vessels as the main manifestation. AAV is a severe disease with high level of mortality. Severity markers are needed to better tailor treatment. ANCA titers have not always been correlated with disease severity and mortality. Other inflammation markers have also been used such as C3 and C-reactive protein (CRP). The aim of this study is to correlate ANCA titers, C3 and CPR values with mortality in patients with renal vasculitis. Method: We retrospectively analyzed all adult patients between June 2006 and December 2022 with a renal AAV in the nephrology department of São Bernardo Hospital. Demographic, clinical and laboratory findings of all patients were recorded. ANCA titers at the time of diagnosis (ANCAd), remission (ANCArm), relapse (ANCArl) and last follow-up (ANCAf) dates were registered. C3 levels were measured at diagnosis (dC3) and at the last follow-up (fC3) dates. CRP was measured at diagnosis (CRPd), remission (CRPrm) and last follow-up (CRPf). ANCA titers was analysed as continuous and categorical variables. C3 and CRP were used as continuous variables. We analyse the association between ANCA titers, C3, CPR values and mortality with univariate analysis. Multivariable adjusted cox regression analysis was performed for assessing predictive variables associated with mortality. Results: We included 58 AAV patients with kidney involvement, with mean age of 69±10 years old, 54.4% were male (n = 31), 82.7% (n = 48) MPO-ANCA+, 12.1% (n = 7) PR3-ANCA+ and 5.2% (n = 3) seronegative. Median follow-up was 32.2 months. 20 (34.5%) patients died. At admission, categorization by ANCA titer revealed 5.2% (3) 0-19 UI/mL, 10.3% (6) 20-39, 8.6% (5) 40-59, 17.2% (10) 60-99, 8.6% (5) 100-134 and 38% >134 (22). C3 median was 109 UI/L at admission, 96.5 UI/L at last follow-up, CPR median was 7.9 mg/dL at admission, 2.4 mg/dL at last follow-up. Univariate analysis did not reveal a difference between patients who survived and those who died, in relation to ANCAd (p = 0.221), ANCArm (p = 0.346), ANCArl (p = 0.180) and ANCAf (p = 0.072). However, it did show that dC3 where significantly lower in those patients who died (p = 0.023) and CRPf higher (p = 0.012), but not for fC3 (p = 0.372), CRPd (p = 0.408) and CRPrm (p = 0.384). Used as categorical variable, ANCAd did not correlate to patients’ death occurrence (p = 0.788). In multivariate analysis including age, gender, dC3 and CRPf, only CRPf was almost significantly (p = 0,06, model p = 0,05). In univariate cox regression analysis to evaluate factors related to survival, none where statistic significant to predict dead – ANCA d (p = 0,349), ANCAf (p = 0.136), dC3 (p = 0.082) and CRPf (p = 0.066). In multivariate cox regression analysis, including age (p = 0.039), gender (p = 0.658), dC3 (p = 0.227) and CRPf (p = 0.639), none factor predict dead (model p = 0,08). Conclusion: In our cohort of patients with AAV, we did not found a serologic marker to predict dead. However, it appears to have a relationship with low serum C3 levels at the time of diagnosis. We also found that could be a relationship with CRP at the last follow-up, but that could be a bias due to higher levels in those how died from infection causes. The diagnostic value of the PR3- and MPO ANCA test is well established, however the relationship between mortality and titer levels in the various stages of the disease is not well established. In our study, there was no association between them. Further research should determine whether C3 levels and CPR are indeed an independent predictor of AAV outcome.
- Open Access
- 14 June 2023
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 38 (Supplement)
#6279 ESKD TREATMENTS: A DIFFICULT CHOICE TO ELDERLY PATIENTS?
End stage kidney disease (ESKD) treatment choice may be very difficult mainly for elderly patients. Dialysis can be burdensome for the frail patients, offering more aggressive procedures and less quality of life. Conservative Care (CC) may shorten life in a fit patient. This study aimed to describe our elderly patients' choices when it comes to CKD treatment options and reflect about them. We designed a single center retrospective observational, cross-sectional study regarding patients (pts) over 80 years old (yo) who attend the appointment of ESKD treatment modalities between July 2015 and and December 2021, since a Conservative Care Program is available in our hospital. During these 6,5 years, 113 pts over 80 yo were attended. Mean age was 85 yo (range 80–103). 66% were male and mean charlson comorbidity index (CMI) was 7 (sd ± 1,2). Mean seric creatinine was 3,69 mg/dl (sd 0,99; range 1,8-7,0). Mean estimated glomerular filtration rate was 17,41 (sd ±4,12) and 14,64 (sd ± 7,6) ml/min per 1.73 m2 when calculated with BIS1 and CKD-EPI equation, respectively. Two patients were already on a regular program of dialysis. Regarding CKD etiology, 31,9% was from multifactorial origin, 27,4% was from undetermined origin, 10,6% was hypertensive, 8% was diabetic, 6,2% was from chronic pyelonephritis and 9,7% was in the context of cardiorenal syndrome. Regarding treatment options, 54% chose hemodialysis, 38,9% chose conservative care (CC), 2,7% chose peritoneal dialysis and 2,7% refused any treatment. We also observed a significant increase in the CC during these 6.5 years of study. Of those who chose hemodialysis, 22,95% (n = 14) died before starting on a regular program of dialysis, 62,3% (n = 38) actually started on a regular program and 14,75% (n = 9) still maintain follow-up in nephrology appointment. Regarding those who died before starting on dialysis treatment, the mean time between choosing dialysis and death was 1,36 years (range 115 days to 5,46 years, median 1,36 years), and between starting on a regular program and death was 1,38 year (range 11 days to 4,9 years). The main cause of death was unknown (66%) (by lack of data), followed by infectious cause (26,6%). Considering those who chose CC, 31,8% (n = 14) died before starting the regular follow up, 54,5% (n = 24) are on a regular program of follow up, and 4,5% (n = 2) lately decided for dialysis. Regarding those who died before CC, the mean time between choosing it and death was approximately 1 year (range 29 days to 3,4 years), and between starting on a regular follow up and death was 0,68 years (range 14 days to 1,7 years). We didn’t find any statistical significance between CMI and the ESRD modality chosen (p = 0.709) or the occurrence of death (p = 0,496). Even considering the poor prognosis and the high mortality rate, the majority of patients over 80 years old still chose dialysis over conservative kidney treatment. In our cohort, there was no survival benefit from those who choose dialysis instead of CC. CC should be offered as an alternative treatment to all the patients who may not benefit from dialysis. It is important to find tools who help us to guide patients in the best suitable choice in regard to ESKD treatments.
- 14 June 2023
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 38 (Supplement)
Open Access#6279 ESKD TREATMENTS: A DIFFICULT CHOICE TO ELDERLY PATIENTS?
End stage kidney disease (ESKD) treatment choice may be very difficult mainly for elderly patients. Dialysis can be burdensome for the frail patients, offering more aggressive procedures and less quality of life. Conservative Care (CC) may shorten life in a fit patient. This study aimed to describe our elderly patients' choices when it comes to CKD treatment options and reflect about them. We designed a single center retrospective observational, cross-sectional study regarding patients (pts) over 80 years old (yo) who attend the appointment of ESKD treatment modalities between July 2015 and and December 2021, since a Conservative Care Program is available in our hospital. During these 6,5 years, 113 pts over 80 yo were attended. Mean age was 85 yo (range 80–103). 66% were male and mean charlson comorbidity index (CMI) was 7 (sd ± 1,2). Mean seric creatinine was 3,69 mg/dl (sd 0,99; range 1,8-7,0). Mean estimated glomerular filtration rate was 17,41 (sd ±4,12) and 14,64 (sd ± 7,6) ml/min per 1.73 m2 when calculated with BIS1 and CKD-EPI equation, respectively. Two patients were already on a regular program of dialysis. Regarding CKD etiology, 31,9% was from multifactorial origin, 27,4% was from undetermined origin, 10,6% was hypertensive, 8% was diabetic, 6,2% was from chronic pyelonephritis and 9,7% was in the context of cardiorenal syndrome. Regarding treatment options, 54% chose hemodialysis, 38,9% chose conservative care (CC), 2,7% chose peritoneal dialysis and 2,7% refused any treatment. We also observed a significant increase in the CC during these 6.5 years of study. Of those who chose hemodialysis, 22,95% (n = 14) died before starting on a regular program of dialysis, 62,3% (n = 38) actually started on a regular program and 14,75% (n = 9) still maintain follow-up in nephrology appointment. Regarding those who died before starting on dialysis treatment, the mean time between choosing dialysis and death was 1,36 years (range 115 days to 5,46 years, median 1,36 years), and between starting on a regular program and death was 1,38 year (range 11 days to 4,9 years). The main cause of death was unknown (66%) (by lack of data), followed by infectious cause (26,6%). Considering those who chose CC, 31,8% (n = 14) died before starting the regular follow up, 54,5% (n = 24) are on a regular program of follow up, and 4,5% (n = 2) lately decided for dialysis. Regarding those who died before CC, the mean time between choosing it and death was approximately 1 year (range 29 days to 3,4 years), and between starting on a regular follow up and death was 0,68 years (range 14 days to 1,7 years). We didn’t find any statistical significance between CMI and the ESRD modality chosen (p = 0.709) or the occurrence of death (p = 0,496). Even considering the poor prognosis and the high mortality rate, the majority of patients over 80 years old still chose dialysis over conservative kidney treatment. In our cohort, there was no survival benefit from those who choose dialysis instead of CC. CC should be offered as an alternative treatment to all the patients who may not benefit from dialysis. It is important to find tools who help us to guide patients in the best suitable choice in regard to ESKD treatments.
- Open Access
- 14 November 2022
- Published by Publicacoes Ciencia e Vida, Lda in Portuguese Journal of Nephrology & Hypertension
- Vol. 36
Palliative Care Competencies in Nephrology: A Scoping Review
- 14 November 2022
- Published by Publicacoes Ciencia e Vida, Lda in Portuguese Journal of Nephrology & Hypertension
- Vol. 36
Open AccessPalliative Care Competencies in Nephrology: A Scoping Review
- Open Access
- 15 July 2022
- Published by Ordem dos Medicos in Acta Medica Portuguesa
- Vol. 35 (10) , 758-764
Anemia da Doença Renal Crónica: O Estado da Arte
O envelhecimento populacional tem-se traduzido no aumento de prevalência de doenças crónicas como a doença renal crónica. A anemia é uma das complicações mais frequentes da doença renal crónica, com impacto não só na qualidade de vida como no prognóstico do doente e nos custos associados. O conhecimento nesta área terapêutica tem aumentado de forma significativa: desde o aparecimento da eritropoietina recombinante em 1989, passando pelo uso de doses crescentes de ferro parentérico e, mais recentemente, a novas moléculas como os inibidores do hypoxia-inducible factor. Os autores pretendem rever, de uma forma pragmática, o estado da arte da anemia associada à doença renal crónica, desde a epidemiologia, à fisiopatologia, ao diagnóstico e ao tratamento.
- 15 July 2022
- Published by Ordem dos Medicos in Acta Medica Portuguesa
- Vol. 35 (10) , 758-764
Open AccessAnemia da Doença Renal Crónica: O Estado da Arte
O envelhecimento populacional tem-se traduzido no aumento de prevalência de doenças crónicas como a doença renal crónica. A anemia é uma das complicações mais frequentes da doença renal crónica, com impacto não só na qualidade de vida como no prognóstico do doente e nos custos associados. O conhecimento nesta área terapêutica tem aumentado de forma significativa: desde o aparecimento da eritropoietina recombinante em 1989, passando pelo uso de doses crescentes de ferro parentérico e, mais recentemente, a novas moléculas como os inibidores do hypoxia-inducible factor. Os autores pretendem rever, de uma forma pragmática, o estado da arte da anemia associada à doença renal crónica, desde a epidemiologia, à fisiopatologia, ao diagnóstico e ao tratamento.
- 5 January 2022
- Published by Publicacoes Ciencia e Vida, Lda in Portuguese Journal of Nephrology & Hypertension
- Vol. 35 (4)
Supportive Care Program in CKD: from dream to reality
The number of older and frail patients has greatly increased in nephrology departments. Traditional treatment options have become inappropriate because they seem unable to achieve goals such as quality of life. Principles from palliative care have been brought to chronic kidney disease management with good results; thus a new way to approach these patients has been reported. In Portugal, in 2011, Direcção Geral de Saúde published a guideline to substantiate supportive care as an option, for certain patients, in certain circumstances. The best evidence known at the time was stated and the conditions that should be met were regulated, but limited information was given about practical implementation of what. In this article we describe our experience with a supportive care program from planning to the implementation steps, since 2015. We reflect on the flowchart, the barriers, the conquests, and the data up to the end of 2020.
- 5 January 2022
- Published by Publicacoes Ciencia e Vida, Lda in Portuguese Journal of Nephrology & Hypertension
- Vol. 35 (4)
Supportive Care Program in CKD: from dream to reality
The number of older and frail patients has greatly increased in nephrology departments. Traditional treatment options have become inappropriate because they seem unable to achieve goals such as quality of life. Principles from palliative care have been brought to chronic kidney disease management with good results; thus a new way to approach these patients has been reported. In Portugal, in 2011, Direcção Geral de Saúde published a guideline to substantiate supportive care as an option, for certain patients, in certain circumstances. The best evidence known at the time was stated and the conditions that should be met were regulated, but limited information was given about practical implementation of what. In this article we describe our experience with a supportive care program from planning to the implementation steps, since 2015. We reflect on the flowchart, the barriers, the conquests, and the data up to the end of 2020.
- Open Access
- 8 October 2021
- Published by Publicacoes Ciencia e Vida, Lda in Portuguese Journal of Nephrology & Hypertension
- Vol. 35 (3)
Choices for life: how can we help?
- 8 October 2021
- Published by Publicacoes Ciencia e Vida, Lda in Portuguese Journal of Nephrology & Hypertension
- Vol. 35 (3)
Open AccessChoices for life: how can we help?